ERBB-2 overexpression as a risk factor for malignant phaeochromocytomas and paraganglinomas-Reference-Cited by-同舟云学术

ERBB-2 overexpression as a risk factor for malignant phaeochromocytomas and paraganglinomas

Published:2016-02-25 Issue:6 Volume:84 Page:822-829
ISSN:0300-0664
Container-title:Clinical Endocrinology
language:en
Short-container-title:Clin Endocrinol

Author:

Wang Weiqing¹²,Zhong Xu¹,Ye Lei¹²,Qi Yan¹,Su TingWei¹,Wei Qing³,Xie Jing³,Jiang Lei¹,Jiang Yiran¹,Zhou Weiwei¹,Cui Bin¹²,Ning Guang¹²

Affiliation:

1. Shanghai Key Laboratory for Endocrine Tumors, Shanghai Clinical Center for Endocrine and Metabolic Diseases, Key Laboratory for Endocrine and Metabolic Diseases of Chinese Health Ministry; Ruijin Hospital, Shanghai Jiao Tong University School of Medicine; 197 Ruijin 2nd Road Shanghai 200025 China

2. Laboratory for Endocrine & Metabolic Diseases of Institute of Health Science; Shanghai Jiao Tong University School of Medicine and Shanghai Institutes for Biological Sciences, Chinese Academy of Sciences; 227 South ChongQing Road Shanghai China

3. Department of Pathology; Ruijin Hospital, Shanghai Jiao Tong University School of Medicine; 197 Ruijin 2nd Road Shanghai China

Funder

National Natural Science Foundation of China

Chinese Clinical Research Center for Metabolic Diseases

National High Technology Research and Development Program of China (863 Program)

Clinical Research Funds of the Chinese Medical Association

Publisher

Wiley

Subject

Endocrinology, Diabetes and Metabolism,Endocrinology

Reference34 articles.

1. Malignant adrenal phaeochromocytoma;Lloyd;WHO classification of tumours: pathology and genetics-tumours of endocrine organs,2004